• Japanese
  • Korean
  • Chinese
Cover Image

MediPoint: Bioabsorbable Stents - EU Analysis and Market Forecasts

Abstract

Summary

GlobalData has released its medical device report, MediPoint: Bioabsorbable Stents - EU Analysis and Market Forecasts. The report is a vital source of up-to-date information with in-depth analysis on the Bioabsorbable Stent (BAS) Market in France, Germany, Italy, Spain and the UK (EU). Provided within is a comprehensive breakdown of opportunities and inhibitors within the major EU BAS markets, highlighting testimonials from physicians from around the world utilizing this technique already. The report identifies and analyzes the key trends shaping and driving the EU Bioabsorbable Stent market. Future EU sales expectations are discussed through careful analysis of Bioabsorbable Stent implantation procedure adoption patterns. The report provides insight into the competitive BAS landscape in the EU, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • An overview of coronary artery disease and peripheral artery disease, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized EU bioabsorbable stent market revenue, future forecasts and procedure patterns data from 2009 to 2011, forecast for 7 years to 2018.
  • Investigation of current and future market competition for Bioabsorbable Stents.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, regulatory approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the EU device sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOLs) as well as interventional cardiologists and interventional radiologists already using these novel devices.

Reasons to buy

  • Understand the trends shaping and driving the EU Bioabsorbable Stent Market.
  • Realize device preferences of physicians who have performed bioabsorbable stent implantations already.
  • Access market sizing, forecasts and quantified growth opportunities in the EU Bioabsorbable Stent Market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess the competitiveness the products in market by understanding the strengths and weaknesses of the current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Coronary Artery Disease
  • 3.2. Peripheral Artery Disease
  • 3.3. Anatomy and Physiology
  • 3.4. Pathophysiology
    • 3.4.1. Coronary Artery Disease
    • 3.4.2. Peripheral Artery Disease
  • 3.5. Clinical Presentation
    • 3.5.1. Symptoms of Coronary Artery Disease (NHLBI, 2011c)
    • 3.5.2. Symptoms of Peripheral Artery Disease (Stoppler, 2012)
    • 3.5.3. Risk Factors
    • 3.5.4. Disease Segments
    • 3.5.5. Diagnosis
  • 3.6. Clinical Outcomes
    • 3.6.1. Treatment Paradigm
    • 3.6.2. Treatment Modalities
    • 3.6.3. Coronary/Peripheral Artery Bypass Grafting
    • 3.6.4. Interventional Cardiology
  • 3.7. Epidemiology
    • 3.7.1. Coronary Artery Disease
    • 3.7.2. Peripheral Artery Disease
  • 3.8. Economic Impact
    • 3.8.1. Coronary Artery Disease
    • 3.8.2. Peripheral Artery Disease
    • 3.8.3. Treatment Costs

4. Competitive Assessment

  • 4.1. Overview
  • 4.2. Absorb BVS - Abbott Vascular
    • 4.2.1. Efficacy

4.2.2. SWOT Analysis

  • 4.3. Remedy - Kyoto Medical Planning
    • 4.3.1. Efficacy

4.3.2. SWOT Analysis

5. Unmet Needs

  • 5.1. Biodegradable and Bioabsorbable Stents
  • 5.2. Reduce Risk of Complications
  • 5.3. Reduce the Need for Stent-in-Stent Procedures
  • 5.4. Long-Term Clinical Data
  • 5.5. Stent Fracture
  • 5.6. Dual Anti-Platelet Therapy
  • 5.7. Imaging

6. Pipeline Products

  • 6.1. Overview
  • 6.2. Pipeline by Phases in Development - Coronary Artery Disease
  • 6.3. Pipeline Product Profiles - Coronary Artery Disease
    • 6.3.1. Igaki-Tamai Stent
    • 6.3.2. ReZolve Sirolimus Eluting Bioabsorbable Coronary Scaffold
    • 6.3.3. Drug-Eluting Absorbable Metal Scaffold
    • 6.3.4. Absorbable Metal Stents
    • 6.3.5. DESolve Bioabsorbable Coronary Scaffold System
    • 6.3.6. ART Stent
    • 6.3.7. The OrbusNeich Stent
    • 6.3.8. TephaFLEX Absorbable Stent
    • 6.3.9. The Arterius Stent
    • 6.3.10. Zorion Medical Stent
    • 6.3.11. 3V Avatar
    • 6.3.12. Biosorb
    • 6.3.13. Summary
  • 6.4. Pipeline by Phases in Development - Peripheral Artery Disease
  • 6.5. Pipeline Product Profiles- Peripheral Artery Disease
    • 6.5.1. Magic Explorer Stent
    • 6.5.2. Esprit Bioabsorbable Vascular Scaffold
    • 6.5.3. ART Stent
    • 6.5.4. TephaFLEX Absorbable Peripheral Stent
    • 6.5.5. Zorion Medical Stent
    • 6.5.6. Amaranth Medical Stent
    • 6.5.7. Summary
  • 6.6. Clinical Trial Analysis
    • 6.6.1. Overview
    • 6.6.2. Trials to Watch

7. Industry Overview

  • 7.1. Procedure Trends
    • 7.1.1. Factors Contributing to Rise of Coronary and Peripheral Interventions
    • 7.1.2. Coronary Artery Disease
    • 7.1.3. Peripheral Artery Disease
  • 7.2. Market Access
    • 7.2.1. Europe
  • 7.3. Reimbursement Trends
    • 7.3.1. Europe
  • 7.4. Regulatory Issues/Recalls

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. Abbott Vascular
    • 8.3.2. Kyoto Medical Planning Co., Ltd
    • 8.3.3. Biotronik SE & Co. KG
    • 8.3.4. REVA Medical, Inc.
    • 8.3.5. Elixir Medical Corporation
    • 8.3.6. Arterial Remodeling Technologies
    • 8.3.7. Tepha, Inc.
    • 8.3.8. OrbusNeich
    • 8.3.9. Arterius
    • 8.3.10. Zorion Medical
    • 8.3.11. S3V Vascular Technologies
    • 8.3.12. ICON Interventional Systems
    • 8.3.13. Amaranth Medical
    • 8.3.14. Medlogics Device Corporation

9. Market Drivers, Opportunities and Barriers

  • 9.1. Market Drivers
    • 9.1.1. Rising Prevalence of Disease
    • 9.1.2. Avoid Stent-in-Stent Procedures
    • 9.1.3. Reduce/Eliminate Dual Anti-Platelet Therapy
    • 9.1.4. Availability of Long-Term Data
    • 9.1.5. Treatment Cost Considerations
    • 9.1.6. Accurate Stent Placement
  • 9.2. Opportunities
    • 9.2.1. Bioabsorbable Stent Market Segmentation
    • 9.2.2. Expand Indications of Bioabsorbable Stenting
    • 9.2.3. Target High-Risk Patients
    • 9.2.4. Improve Deliverability of Bioabsorbable Stents
    • 9.2.5. Emerging Markets
  • 9.3. Market Barriers
    • 9.3.1. Slow Adoption
    • 9.3.2. Complications with Bioabsorbable Stents
    • 9.3.3. High Selling Price
    • 9.3.4. Reimbursement
    • 9.3.5. Substitutes

10. Country Outlooks and Forecasts

  • 10.1. European Market Overview
  • 10.2. France
    • 10.2.1. Overview
    • 10.2.2. Market Analysis
  • 10.3. Germany
    • 10.3.1. Overview
    • 10.3.2. Market Analysis
  • 10.4. Italy
    • 10.4.1. Overview
    • 10.4.2. Market Analysis
  • 10.5. Spain
    • 10.5.1. Overview
    • 10.5.2. Market Analysis
  • 10.6. United Kingdom
    • 10.6.1. Overview
    • 10.6.2. Market Analysis

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Report Methodology
    • 11.3.1. Overview
    • 11.3.2. Coverage
    • 11.3.3. Secondary Research
    • 11.3.4. Forecasting Methodology
  • 11.4. Physicians and Specialists Included in this Study
  • 11.5. Physician Survey
  • 11.6. About the Authors
    • 11.6.1. Analysts
    • 11.6.2. Global Head of Healthcare
  • 11.7. About MediPoint
  • 11.8. About GlobalData
  • 11.9. Contact Us
  • 11.10. Disclaimer

List of Tables

  • Table 1: Risk Factors Associated with Coronary Artery Disease
  • Table 2: Risk Factors Associated with Peripheral Artery Disease
  • Table 3: Types of Coronary Artery Bypass Grafting
  • Table 4: Drugs Incorporated into Drug-Eluting Stents
  • Table 5: Total Prevalence of CAD in ≥65 population in the Major European Markets, millions
  • Table 6: Total Prevalence of PAD Among ≥65 Population in the Major European Markets, millions
  • Table 7: Description of Direct and Indirect Economic Costs
  • Table 8: Economic Impact ($bn) of CAD in Europe
  • Table 9: Economic Impact ($bn) of PAD in Europe*
  • Table 10: Hospital Charges for Interventional Cardiology Procedures in the US
  • Table 11: Marketed Bioabsorbable Stent Products
  • Table 12: Absorb BVS Product Portfolio
  • Table 13: Absorb BVS SWOT Analysis, 2012
  • Table 14: Remedy Stent Product Portfolio
  • Table 15: Remedy SWOT Analysis, 2012
  • Table 16: BAS Product Pipeline (Coronary)
  • Table 17: Igaki-Tamai Stent SWOT Analysis, 2012
  • Table 18: ReZolve Stent SWOT Analysis, 2012
  • Table 19: DREAMS SWOT Analysis, 2012
  • Table 20: AMS SWOT Analysis, 2012
  • Table 21: BAS Product Pipeline (Peripheral)
  • Table 22: Magic Explorer Stent SWOT Analysis, 2012
  • Table 23: Esprit BVS SWOT Analysis, 2012
  • Table 24: Company Profile - Abbott Vascular
  • Table 25: Marketed Bioabsorbable Stent Products by Abbott Vascular
  • Table 26: Pipeline Bioabsorbable Stent Products by Abbott Vascular
  • Table 27: Abbott Vascular SWOT Analysis, 2012
  • Table 28: Company Profile - Kyoto Medical Planning
  • Table 29: Marketed Bioabsorbable Stent Products by Kyoto Medical Planning
  • Table 30: Pipeline Bioabsorbable Stent Products by Kyoto Medical Planning
  • Table 31: Kyoto Medical Planning SWOT Analysis, 2012
  • Table 32: Company Profile - Biotronik
  • Table 33: Pipeline Bioabsorbable Stent Products by Biotronik
  • Table 34: Biotronik SWOT Analysis, 2012
  • Table 35: Company Profile - REVA Medical
  • Table 36: Pipeline Bioabsorbable Stent Products by REVA Medical
  • Table 37: REVA Medical SWOT Analysis, 2012
  • Table 38: Company Profile - Elixir Medical Corporation
  • Table 39: Pipeline Bioabsorbable Stent Products by Elixir Medical Corporation
  • Table 40: Elixir Medical Corporation SWOT Analysis, 2012
  • Table 41: Company Profile - Arterial Remodeling Technologies
  • Table 42: Pipeline Bioabsorbable Stent Products by Arterial Remodeling Technologies
  • Table 43: Arterial Remodeling Technologies SWOT Analysis, 2012
  • Table 44: Company Profile - Tepha
  • Table 45: Pipeline Stent Products by Tepha
  • Table 46: Tepha SWOT Analysis, 2012
  • Table 47: Company Profile - OrbusNeich
  • Table 48: Pipeline Bioabsorbable Stent Products by OrbusNeich
  • Table 49: OrbusNeich SWOT Analysis, 2012
  • Table 50: Company Profile - Arterius
  • Table 51: Arterius SWOT Analysis, 2012
  • Table 52: Company Profile - Zorion Medical
  • Table 53: Zorion Medical SWOT Analysis, 2012
  • Table 54: Company Profile - S3V Vascular Technologies
  • Table 55: S3V Vascular Technologies SWOT Analysis, 2012
  • Table 56: Company Profile - ICON Interventional Systems
  • Table 57: ICON Interventional Systems SWOT Analysis, 2012
  • Table 58: Company Profile - Amaranth Medical
  • Table 59: Amaranth Medical SWOT Analysis, 2012
  • Table 60: Company Profile - Medlogics Device Corporation
  • Table 61: Medlogics Device Corporation SWOT Analysis, 2012
  • Table 62: Sales ($m) Forecast for Bioabsorbable Stents in the EU5* Markets, 2011-2018
  • Table 63: Bioabsorbable Stent Sales ($m) Forecast in France, 2011-2018
  • Table 64: Bioabsorbable Stent Sales ($m) Forecast in Germany, 2011-2018
  • Table 65: Bioabsorbable Stent Sales ($m) Forecast in Italy, 2011-2018
  • Table 66: Bioabsorbable Stent Sales ($m) Forecast in Spain, 2011-2018
  • Table 67: Bioabsorbable Stent Sales ($m) Forecast for United Kingdom, 2011-2018
  • Table 68: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Anatomy of the Human Heart
  • Figure 2: Pathophysiology of Coronary Artery Disease
  • Figure 3: Pathophysiology of Peripheral Artery Disease
  • Figure 4: Treatment Modalities - Coronary Artery Disease
  • Figure 5: Interventional Cardiology Procedures for Treating CAD, US and Europe, 2012
  • Figure 6: Treatment Modalities - Peripheral Artery Disease
  • Figure 7: Interventional Cardiology for Treating PAD, US and Europe, 2012
  • Figure 8: Types of Stents
  • Figure 9: Prevalence of CAD in Population ≥65 Years in the Major European Markets
  • Figure 10: Percent of Patients (≥65 years) Treated for CAD, US and Europe
  • Figure 11: Prevalence of PAD in Population ≥65 Years in the Major European Markets
  • Figure 12: Direct and Indirect Costs ($bn) of CAD in Europe
  • Figure 13: Total Costs ($bn) of PAD in Europe
  • Figure 14: US Hospital Charges for Interventional Procedures, 2011-2018
  • Figure 15: Importance of a Biodegradable and Absorbable Stent to Physicians in Europe (n=30)
  • Figure 16: Percent of Patients with CAD Patients Experiencing Complications after Drug-Eluting Stenting, 2012 (n=15)
  • Figure 17: Percent of Patients with PAD Patients Experiencing Complications after Drug-Eluting Stenting, 2012 (n=15)
  • Figure 18: Percent of Patients (≥ 65 years) with CAD Receiving Stent-in-Stent Procedures, 2012 (n=15)
  • Figure 19: BAS Coronary Pipeline by Stage in Clinical Development, 2012
  • Figure 20: BAS Peripheral Pipeline by Stage in Clinical Development, 2012
  • Figure 21: Population (≥ 65 years) with CAD Receiving Interventional Procedures in Europe*
  • Figure 22: Population (≥ 65 years) with PAD Receiving Interventional Procedures in Europe*
  • Figure 23: Likelihood of Physicians Adopting Bioabsorbable Stents in Europe, 2012 (n=30)
  • Figure 24: Kyoto Medical Planning Co., Ltd. Sales Volume ($m), May 2002-May 2012
  • Figure 25: EU5* Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 26: Bioabsorbable Stents Total Revenue in the EU5* Markets
  • Figure 27: French Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 28: German Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 29: Italian Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 30: Spanish Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 31: UK Bioabsorbable Stent Market ($m), 2011-2018
Show More
Pricing
Get Notified
Email me when related reports are published